comparing the efficacy and safety of vonoprazan with PPIs for GERD, has been published. Results show that vonoprazan is non-inferior to PPIs as therapy for patients with GERD (RR: 1.06 – 95% C.I. 0.99–1.13). However, subgroup analysis indicates that ...
Correction to: Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid BlockersGERDH. pyloriinfectionNSAID gastropathyUpper GI bleedingUnmet clinical needsPPIsP-CABsVonoprazanTegoprazanFexuprazanPurpose of the review The introduction of H2-receptor antagonists (H2RAs) and proton pump ...
PPIs are now the standard of care for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), Helicobacter pylori infection, NSAID-associated gastroduodenal lesions, and upper gastrointestinal bleeding (UGIB). However, despite their effectiveness, PPIs display some intrinsic...
▸ Erosive Esophagitis, Poorly Responsive GERD, Active Duodenal Ulcer, Prevention and Treatment of NSAID-Induced Ulcers PO Adults, Elderly. 20 mg/day. ▸ To Maintain Healing of Erosive Esophagitis PO Adults, Elderly. 20 mg/day. ▸ Pathologic Hypersecretory Conditions ...
Gerd KonzenOtto HauswirthNaunyn Schmiedebergs Arch PharmacolNaunyn-Schmiedeberg's archives of pharmacologyReichardt B, Konzen G, Hauswirth O (1990) Pirmenol, a new antiarrhythmic drug with potassium- and sodium-channel blocking activity: a voltage-clamp study in rabbit Purkinje fibres. NaunynSchmiedeberg...